•The combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence or death by 28% in patients with earlier-stage renal cell carcinoma (RCC).
•WELIREG plus LENVIMA reduced the risk of disease progression or death by 30% compared to cabozantinib in certain previously treated patients with advanced RCC.